Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
HiRisk schreef op 7 januari 2018 21:40 :
[...]Welke Paddo's gebruik jij?
Moest FF hartelijk lachen...Abtje
www.participaties.nl/Forum/Upload/201... Dit is nog wel oud nieuws van tKanVriezenDooien uit het Pharming het aandeel van 2017, Datum: 14 oktober 2017 Ik hoop dat iemand daar nog wat aan heeft met het idee dat schema wel hoger kunt opschalen....
HiRisk schreef op 7 januari 2018 21:40 :
[...]Welke Paddo's gebruik jij?
waarschijnlijk buitenlandse en is de schrijver onze taal niet machtig ,de vertaal programma's zijn ook nog niet alles.
OP ZOEK NAAR DE KASKRAKER Nico Inberg Crucell, Galapagos en Pharming: eigenlijk vertellen deze drie beroemde biotechnologiebedrijven uit de Lage Landen het hele verhaal wat beleggen in biotech onweerstaanbaar en misschien wel verslavend maakt. De gok, de fantasie, de belofte, de hoop en wanhoop, de koersexplosies en –implosies én uiteindelijk soms de hoofdprijs: een blockbuster in de apotheekschappen, of een mooie overname. Zo kocht Johnson & Johnson uiteindelijk in 2011 voor veel geld Crucell op. Beleggen in biotech is een sport apart. Een correcte waardering voor de bedrijven is moeilijk, of niet, te maken. Het gaat niet om het taxeren van omzet en winst - vaak zijn die er helemaal niet - maar om het inschatten van de kans van slagen van een of meerdere medicijnen in ontwikkeling. Hierdoor bewegen de koersen van biotechaandelen vaak hard op en neer en dat trekt handelaren en speculanten aan. Tenslotte kan goed- of afkeuring van een kandidaat-geneesmiddel een bedrijf maken of breken. Vaak zien we uitslagen van plus of minus 50% of nog meer op Wall Street in de biotechsector. Niet op cijfers, zoals bij de meeste andere bedrijven, maar op persberichten met goed of slecht nieuws.
MEER DAN GOKAANDELEN Toch zijn biotechs meer dan louter holderdebolder-aandelen. De bedrijven zijn vaak ontstaan in de academische gezondheidszorg, waar professoren en artsen door research op het spoor van een nieuw medicijn komen. Verdere vergrijzing en toename van chronische ziekten vormen een vruchtbare bodem voor de almaar verdergaande ontwikkelingen in de biotechnologie. VEEL GELD NODIG Voor verdere ontwikkeling is veel geld nodig en dat is waar de eerste investeerders aan boord komen. De meeste biotech start-ups willen zo snel mogelijk naar de beurs, om verdere toegang tot kapitaal mogelijk te maken. Onderzoek duurt namelijk, mede door de strenge eisen, vaak langer dan verwacht en hierdoor is een grote kaspositie onontbeerlijk. SCHRALE TROOST Een schrale troost voor beleggers die vooral pech hebben met biotechaandelen is dat ze uiteindelijk zorgen voor een betere gezondheidszorg. U hebt daar dan, misschien onvrijwillig, toch maar uw steentje aan bijgedragen. Ook al bent u zelf bijna al uw geld kwijt…
FASE I In Fase I van de klinische studies wordt een experimenteel geneesmiddel, ook wel een Investigational New Drug, voor het eerst onderzocht bij menselijke (gezonde) proefpersonen. De dosering van het nieuwe geneesmiddel wordt geleidelijk verhoogd, zodat de onderzoeker de klinische respons op het geneesmiddel kan meten. FASE II Focus op effectiviteit, bijwerkingen en mogelijke risico's. Bepaling van de meest effectieve dosering en meest geschikte manier van toedienen (infuus, injectie etcetera). FASE III Onderzoek in grotere populatie voor aanvullende informatie. Dit onderzoek is vaak dubbelblind (zowel onderzoeker als patiënt weten niet of ze een placebo of het echte middel krijgen). REGISTRATIE Aanvraag registratie bij toezichthouder. In de VS bij FDA, in Europa bij EMA, dat volgend jaar van Londen naar Amsterdam verhuist. Na goedkeuring kan het geneesmiddel op de markt worden gebracht. FASE IV Post-marketing studie: bedoeld om aanvullende informatie te krijgen over langetermijneffecten en optimaal gebruik. Gaat vaak om duizenden proefpersonen. Bron: Pfizer.nl
1 PHARMING €1,21 KERNGEGEVENS (IN €) Verwachte omzet 2017 0,09 mrd Verwachte winst 2017 -0,01 p.a. Beurswaarde 0,57 mrd Hoogste koers 52 wk 1,34 Laagste koers 52 wk 0,22
FUNDAMENTEEL: BIG PHARMING Natuurlijk gaan we Pharming opnieuw goed volgen dit jaar. De ontwikkeling vorig jaar was spectaculair. Het terugkopen van de verkooprechten in de VS bleek een briljante zet. Topman Sijmen de Vries kreeg het verkoopteam in de VS goed op stoom en had ook nog eens het geluk dat concurrent Shire in leveringsproblemen kwam. Strikt genomen is Pharming NU geen biotechbedrijf meer, maar een farmaceut, het brengt namelijk al een product op de markt. Dat is meteen ook een groot risico: Pharming is afhankelijk van slechts dat ene product. De omzetcijfers over Q4 worden belangrijk: we weten dat die sterk worden, de vraag is alleen hoe sterk. En een andere koerstrigger is de goedkeuring voor prophylaxe: het gebruik van Ruconest als preventief middel. Ook hierover verwachten we in 2018 meer nieuws. Zo nu en dan zal er nog wel wat verwatering optreden door uitoefening van warrants en converteerbare obligaties. LEES HIER DE LAATSTE UPDATE VAN DE IEX BELEGGERSDESK
Pharming is binnen de stijgende trend, rond weerstand 1,35 (gevormd op 2 september 2011), het koersdoel genaderd. De stijgende trend krijgt pas een nieuwe impuls indien deze top wordt gebroken. In dat geval mag men verdere koersstijgingen tegemoet zien, richting 1,97 (top van maart 2011). Pas na een uitbraak boven 1,35 kopen we bij. Wie de stukken heeft blijft zitten. Nieuwe kopers wachten een uitbraak af.
Wordt leuk leuker leukst komende maanden....:::—-)))
Pigeonman: dhr. De. Vries is slim genoeg om dit zelf te bedenken of zijn adviseurs geven hem wel raad of misschien leest hij ook wel eens dit forum. Geduld is een schone zaak.
leon 55 schreef op 7 januari 2018 21:58 :
[...]
Moest FF hartelijk lachen...Abtje
Ik ook..., nog een AB-tje voor Hirisk.
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib A New Drug Application (NDA) submission for fedratinib in myelofibrosis is planned for mid-2018 SUMMIT, N.J. & SAN DIEGO --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible. Fedratinib, a highly selective JAK2 kinase inhibitor, was evaluated in 877 patients across 18 clinical trials. In a randomized, placebo-controlled, phase III pivotal trial ( JAKARTA -1) for patients with treatment-naïve myelofibrosis, fedratinib demonstrated statistically significant improvements in the primary and secondary endpoints of splenic response and total symptom score, respectively. In an exploratory subgroup analysis, these improvements were observed regardless of a patient's baseline platelet count. A multi-center, single-arm phase II trial ( JAKARTA -2) evaluated fedratinib in myelofibrosis patients who were found to be resistant or intolerant to ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor. In this second-line setting, fedratinib demonstrated clinically meaningful improvements in splenic response and total symptom score. As previously reported, JAKARTA -2 was stopped prematurely due to a clinical hold placed on the fedratinib program by the U.S. Food and Drug Administration (FDA) after potential cases of Wernicke's encephalopathy (WE) were reported in eight out of 877 patients receiving one or more doses (less than one percent of treated patients). The FDA removed the clinical hold in August 2017 . Based on the reported benefit risk profile of fedratinib from the JAKARTA -1 and JAKARTA -2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018. "Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase," said Nadim Ahmed , President, Hematology and Oncology for Celgene . "We believe fedratinib is uniquely positioned as a potential treatment for myelofibrosis and it provides strategic options for us to build leadership in this disease with luspatercept and other pipeline assets." "We launched Impact Biomedicines and based on our thorough review of the data, fedratinib presents a compelling risk benefit profile in both treatment-naïve patients and patients who are resistant or intolerant to other JAK2 therapies," said Dr. John Hood , Chief Executive Officer of Impact. "We believe Celgene is the ideal organization to follow through on our mission of maximizing fedratinib's potential for patients with myelofibrosis." Deal Terms Under the terms of the agreement, Celgene will make an upfront cash payment of approximately $1.1 billion . In addition, Impact Biomedicines's shareholders are eligible to receive contingent payments based on regulatory approval and sales-based milestones. The maximum aggregate amount payable for regulatory approval milestones is $1.4 billion relating to approvals for myelofibrosis and other indications. Starting from global annual net sales of $1.0 billion , aggregate tiered sales-based milestone payments could total a maximum of $4.5 billion if global annual net sales exceed $5.0 billion . Credit Suisse acted as financial advisor and Hogan Lovells acted as legal counsel to Celgene on the transaction. PJT Partners acted as exclusive financial advisor and Latham & Watkins acted as exclusive legal counsel to Impact Biomedicines on the transaction. The acquisition is subject to customary closing conditions and applicable waiting period under the Hart Scott Rodino Antitrust Improvements Act. The transaction is expected to close in the first quarter of 2018. About Celgene Celgene Corporation , headquartered in Summit, New Jersey , is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube. About Impact Biomedicines Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company's pipeline is centered around fedratinib, a highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was financed by Medicxi and Oberland Capital . Forward-Looking Statement This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission . Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
The Bio/Pharma acquisition hunt is officially opened caused by the huge corporate tax cuts. Get ready for a large biotech run (biotech multiples might increase 50%)
Wall Street Journal - Drug Industry Is Ripe for a Wave of Deals In addition to those discussed in WSJ below, I had heard the new tax deal repatriation terms say that US companies have to segregate foreign cash into the amount to be repatriated and the amount to stay oversees.....and have to pay taxes on the repatriation amount even if still overseas...so it makes sense the money would come back to US quickly. www.wsj.com/articles/drug-industry-is... Drug Industry Is Ripe for a Wave of Deals Big pharma and biotech aren’t benefiting as much from higher drug prices, raising the possibility of large deals 8:10 AM ET 01/05/2018 Nearly a decade ago, a wave of megamergers gripped the pharmaceutical industry. In 2018, conditions are right for a sequel. Back then, concerns about growth and tougher regulations spurred deals like Pfizer(PFE)'s $68 billion acquisition of Wyeth and Merck(MRK) & Co.'s $41 billion acquisition of Schering-Plough. Today, growth concerns are rising again, and several other factors, including consolidation in other parts of health care, are setting the stage for another wave of deals. Drugmakers have relied on price increases for a big portion of their recent growth, but those are getting harder to push through. True, pharmaceutical companies boosted list prices as usual when the calendar turned to the new year, but raising prices doesn't pack the same punch as it did in years past. Now, consolidation among insurers and pharmacy-benefit managers means drugmakers are seeing a smaller share of those hikes than in recent years, while money paid as rebates to PBMs increases. "Biopharma companies now have a reduced ability to increase net, realized price in the U.S." compared to the status quo since 2010, analysts at Leerink Partners said in a note last month. Buying up smaller biotech startups has also helped boost growth rates for big pharma companies. But years of brisk acquisitions means that there is now a relative scarcity of targets with drugs that are close to generating revenue and have strong enough sales potential to move the needle for bigger outfits. Consider in 2016, Pfizer bought Medivation, which had a blockbuster cancer drug already on the market, for $14 billion). Gilead Sciences(GILD) bought Kite Pharma for a similar price last summer, but Gilead doesn't expect that deal to contribute to earnings for several years. Balance sheets within this group are generally strong enough to absorb larger-scale transactions, while debt capital remains extremely cheap. And company executives finally have clarity on U.S. tax policy after a long period of uncertainty. There is no shortage of opportunities for partnering. More than 20 branded drug companies have projected 2018 revenues above $10 billion, according to FactSet. The main obstacles to deals are regulatory approval and integration concerns, which are particularly important because the companies in question are so large For big pharma, a new set of challenges could lead to a familiar solution. (END) Dow Jones Newswires
by Rob Coz from the Ziop message board (I hold a long position in Ziop): Jefferies Yee - Americas / Biotechnology: 3 thoughts and themes we’re focused on into the madness this week… I have emailed Yee with the Brad Loncar JPM week bio performance which is usually positive (see twitter link) and Yee told me he expects a sector rally this week. Hope he is right. twitter.com/bradloncar/status/9493258... Americas / Biotechnology: 3 thoughts and themes we’re focused on into the madness this week… Key Takeaway The start of 2018 has been marked by a minor (early) rally in biotech and although encouraging, obviously far too early to be calling any theme. Indeed we look forward to a ton of information flow this week that should more fully drive our sector thesis and idea generation for 2018. Top ideas in large cap remain VRTX, CELG, AMGN; and smid-cap with key data coming: ASMB, ESPR, FGEN, PRTA. As healthcare investors brace for a long week, we will be busy with our own agenda of 30+ public/private company meetings in San Francisco...3 Thoughts: We remain positive and believe both large and smid cap biotech can move higher this year based on an improving backdrop and driven by: (1) market view that tax reform is a tailwind for capital deployment which is great for large-biotechs and large-pharma AND good for smid-biotech M&A opportunities, (2) “catch-up bounce” i.e. large-cap laggards in 2017 could bounce in 2018 as we continue to move away from political rhetoric and fear factors around drug pricing - sentiment and buying interest for this “cheap sector” which has lagged the market could pick up; we think 2018 guidance should be relatively fine for most of large biotech (or at least viewed as conservative and achievable) which could be an overhang removed…(3) tons of catalysts in smid-cap biotech will move these stocks (see Top 30 events list here) and risk/reward has been pretty good (we count 14 biotechs over $1B cap that were up more than 200% in 2017 - email us for list) and hence we can see why good news/data can drive stocks higher… Bear case on the group remains: (1) large biotech still faces top line headwinds (biosimilars or generics against big blockbusters) that make these stocks challenging, it's cheap but valuation isn’t a catalyst and there isn’t a compelling secular growth thesis yet in large biotech, (2) M&A hasn’t happened and isn’t happening much, (3) if nothing has changed, then winners keep working (med tech, tools, etc.) and there’s no reason to rotate out to try and be a hero…(4) mid-term elections…mid-term elections….mid-term elections… 3 themes we will be focused on during the week: (1) Mgmt commentary and investor perception around M&A for 2018. With over $150B+ in biopharma cash to be repatriated, there is a heightened view on M&A in biotech in 2018. In 2016, the sector was in freefall….in 2017 the sector was getting comfortable in a new political environment. In 2018 we could see “mega-merger” potential from big pharma buying big biotech or big biotech buying Smid-biotech….all of these would be reasons for the group to move higher…(2 sub-$2B M&A deals in biotech in last month and ACOR may now be up for sale, see note here). (2) Trading action in biotech during the week and a post-week rally or sell-off? The set-up seems relatively positive given the broader market backdrop continues well which should support “laggards” to try to move higher (GILD, BIIB, etc. have moved up early). Some years have seen a “post-conference sell-off” perhaps due to a move up the week before or because there is the potential for lots of capital raising by smid-caps…But we think there have been such low expectations on the group that if we see a post-selloff, we think the dip would get bought… we could just as much see a “post-conference rally” for all the reasons discussed above…if we see either dynamic (rally or buying dips), this is a positive sign that the market wants to get more positive on biotech and is what we believe is happening in the broader market. (3) Just surviving….the goal of our week and for most investors is just surviving…we will work to get as much information flow as possible while drinking out of a firehose and we’ll have some conclusions. We think a positive is to just get past this week and get to earnings season where 2018 guidance and outlooks should be just fine (particularly on tax reform and relatively low expectations)…and a further reason the group could move up.
Als de uitoefening van warrants en converteerbare obligaties vandaag uitblijft is dit een indicator dat de 43 kwartaalcijfers wel eens boven verwachting kunnen zijn. We gaan dan verder omhoog naar het koersdoel van Stiffel € 1,60. Kind regards, Forecast.
Forecast2006 schreef op 8 januari 2018 06:39 :
Als de uitoefening van warrants en converteerbare obligaties vandaag uitblijft is dit een indicator dat de 43 kwartaalcijfers wel eens boven verwachting kunnen zijn.
We gaan dan verder omhoog naar het koersdoel van Stiffel € 1,60.
Kind regards,
Forecast.
Waarom specifiek vandaag? Waarom zie je dit als een indicator?
Theoretical Opening Price €1,252 08/01/2018 07:17 CET
Na TIG nu ook ABL overnamebod
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)